CAMP4 Therapeutics Corp’s recent filing unveils that its 10% Owner Northpond Ventures II GP, LLC acquired Company’s shares for reported $8.4 million on Oct 15 ’24. In the deal valued at $11.00 per share,763,636 shares were bought. As a result of this transaction, Northpond Ventures II GP, LLC now holds 763,636 shares worth roughly $3.97 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, AH Equity Partners Bio I, L.L. bought 727,272 shares, generating $7,999,992 in total proceeds. Upon buying the shares at $11.00, the 10% Owner now owns 1,579,885 shares.
Before that, Enavate Sciences GP, LLC bought 1,363,636 shares. CAMP4 Therapeutics Corp shares valued at $14,999,996 were divested by the 10% Owner at a price of $11.00 per share. As a result of the transaction, Enavate Sciences GP, LLC now holds 3,785,802 shares, worth roughly $19.69 million.
William Blair initiated its CAMP4 Therapeutics Corp [CAMP] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early November with a ‘”an Overweight”‘ rating. JP Morgan began covering CAMP with “an Overweight” recommendation on November 05, 2024.
Price Performance Review of CAMP
On Friday, CAMP4 Therapeutics Corp [NASDAQ:CAMP] saw its stock fall -2.62% to $5.20. Over the last five days, the stock has lost -31.85%. CAMP4 Therapeutics Corp shares have fallen nearly -51.49% since the year began.
Levels Of Support And Resistance For CAMP Stock
The 24-hour chart illustrates a support level at 4.44, which if violated will result in even more drops to 3.67. On the upside, there is a resistance level at 6.14. A further resistance level may holdings at 7.07. The Relative Strength Index (RSI) on the 14-day chart is 40.86, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.88, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.47%. Stochastics %K at 12.06% indicates the stock is a buying.
